Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).
Publication
, Conference
Clarke, JM; Wang, XF; Gu, L; Stevenson, MM; Stinchcombe, T; Ramalingam, S; Antonia, SJ; Shariff, A; Garst, J; Crawford, J; Ready, NE
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Clarke, J. M., Wang, X. F., Gu, L., Stevenson, M. M., Stinchcombe, T., Ramalingam, S., … Ready, N. E. (2020). Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Clarke, Jeffrey Melson, Xiaofei F. Wang, Lin Gu, Marvaretta Miesha Stevenson, Tom Stinchcombe, Sundhar Ramalingam, Scott Joseph Antonia, et al. “Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Clarke JM, Wang XF, Gu L, Stevenson MM, Stinchcombe T, Ramalingam S, et al. Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.
Clarke, Jeffrey Melson, et al. “Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.
Clarke JM, Wang XF, Gu L, Stevenson MM, Stinchcombe T, Ramalingam S, Antonia SJ, Shariff A, Garst J, Crawford J, Ready NE. Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences